Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $187.50 short put and a strike $182.50 long put offers a potential 37.36% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $187.50 by expiration. The full premium credit of $1.36 would be kept by the premium seller. The risk of $3.64 would be incurred if the stock dropped below the $182.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 32.16 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
See what the IHS Markit Score report has to say about Amgen Inc.
Tue, 06 Nov 2018 13:00:10 +0000
Amgen Inc NASDAQ/NGS:AMGN
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
Mon, 05 Nov 2018 22:50:10 +0000
Amgen (AMGN) closed the most recent trading day at $189.92, moving +1.53% from the previous trading session.
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Mon, 05 Nov 2018 21:00:00 +0000
THOUSAND OAKS, Calif., Nov. 5, 2018 /PRNewswire/ — Amgen (AMGN) today announced the presentation of 10 scientific research abstracts, including the final report of the OSLER-1 study, evaluating the long-term safety and efficacy of Repatha® (evolocumab) in patients with hypercholesterolemia for up to five years. Additional abstracts to be presented include a sub-analysis of the Repatha cardiovascular outcomes study (FOURIER), investigating the effects of triglycerides on cardiovascular risk in patients with established cardiovascular disease, and an evaluation of the utilization of lipid-lowering therapies in patients at high risk for cardiovascular events in a real-world setting. “Despite recent advances in the secondary prevention of cardiovascular events, including heart attack and stroke, many patients with cardiovascular disease do not meet, and may not even be aware of, their recommended low-density lipoprotein cholesterol (LDL-C) goals, putting them at increased risk for cardiovascular events,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Mon, 05 Nov 2018 14:00:00 +0000
THOUSAND OAKS, Calif. and OLDWICK, N.J., Nov. 5, 2018 /PRNewswire/ — Amgen (AMGN) and Provention Bio, Inc. (PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714.
3 Top Biotech Stocks With P/Es Below 14
Sat, 03 Nov 2018 20:52:00 +0000
After a rough month, three top drugmakers are trading at bargain-basement prices.
Also on Market Tamer…
Follow Us on Facebook